Published in Nature on March 05, 2009
Antibiotics for emerging pathogens. Science (2009) 7.39
Challenges of antibacterial discovery. Clin Microbiol Rev (2011) 3.94
A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun (2010) 2.49
Essentiality of FASII pathway for Staphylococcus aureus. Nature (2010) 1.77
Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. Proc Natl Acad Sci U S A (2011) 1.72
Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. Antimicrob Agents Chemother (2012) 1.52
Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. Proc Natl Acad Sci U S A (2011) 1.43
Blueprint for antimicrobial hit discovery targeting metabolic networks. Proc Natl Acad Sci U S A (2010) 1.42
Bacterial lipids: metabolism and membrane homeostasis. Prog Lipid Res (2013) 1.42
Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery? Curr Opin Microbiol (2011) 1.34
Antibacterials from the sea. Chemistry (2010) 1.25
Parallel exploitation of diverse host nutrients enhances Salmonella virulence. PLoS Pathog (2013) 1.24
Membrane disruption by antimicrobial fatty acids releases low-molecular-weight proteins from Staphylococcus aureus. J Bacteriol (2012) 1.24
Comparative genomic analysis of pathogenic and probiotic Enterococcus faecalis isolates, and their transcriptional responses to growth in human urine. PLoS One (2010) 1.23
Staphylococcus aureus FabI: inhibition, substrate recognition, and potential implications for in vivo essentiality. Structure (2012) 1.22
The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob Agents Chemother (2011) 1.21
Systems-level antimicrobial drug and drug synergy discovery. Nat Chem Biol (2013) 1.19
The transcriptome of the nosocomial pathogen Enterococcus faecalis V583 reveals adaptive responses to growth in blood. PLoS One (2009) 1.15
Dedicated ent-kaurene and ent-atiserene synthases for platensimycin and platencin biosynthesis. Proc Natl Acad Sci U S A (2011) 1.15
The role of medical structural genomics in discovering new drugs for infectious diseases. PLoS Comput Biol (2009) 1.11
Pathway analysis of Candida albicans survival and virulence determinants in a murine infection model. Proc Natl Acad Sci U S A (2010) 1.10
Novel anti-infective compounds from marine bacteria. Mar Drugs (2010) 1.08
Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252. Antimicrob Agents Chemother (2013) 1.06
Identification of a two-component fatty acid kinase responsible for host fatty acid incorporation by Staphylococcus aureus. Proc Natl Acad Sci U S A (2014) 1.05
Rational optimization of drug-target residence time: insights from inhibitor binding to the Staphylococcus aureus FabI enzyme-product complex. Biochemistry (2013) 1.05
Remodelling of the Vibrio cholerae membrane by incorporation of exogenous fatty acids from host and aquatic environments. Mol Microbiol (2010) 1.04
Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds. Curr Top Med Chem (2012) 1.03
Productive steps toward an antimicrobial targeting virulence. Curr Opin Microbiol (2009) 1.02
Fatty acid biosynthesis in Pseudomonas aeruginosa is initiated by the FabY class of β-ketoacyl acyl carrier protein synthases. J Bacteriol (2012) 1.01
Optical control of antibacterial activity. Nat Chem (2013) 1.01
Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matching. J Med Chem (2011) 1.01
How bacterial pathogens eat host lipids: implications for the development of fatty acid synthesis therapeutics. J Biol Chem (2015) 0.99
Staphylococcus aureus fatty acid auxotrophs do not proliferate in mice. Antimicrob Agents Chemother (2013) 0.99
Total synthesis of platensimycin and related natural products. J Am Chem Soc (2009) 0.99
Fatty acid synthase impacts the pathobiology of Candida parapsilosis in vitro and during mammalian infection. PLoS One (2009) 0.99
Branched-chain fatty acids promote Listeria monocytogenes intracellular infection and virulence. Infect Immun (2010) 0.98
Carbonic anhydrase is essential for Streptococcus pneumoniae growth in environmental ambient air. J Bacteriol (2010) 0.97
Development and analysis of an in vivo-compatible metabolic network of Mycobacterium tuberculosis. BMC Syst Biol (2010) 0.96
Lipid synthesis in protozoan parasites: a comparison between kinetoplastids and apicomplexans. Prog Lipid Res (2013) 0.96
Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase. J Med Chem (2010) 0.95
Environmental DNA-encoded antibiotics fasamycins A and B inhibit FabF in type II fatty acid biosynthesis. J Am Chem Soc (2012) 0.94
Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei. J Antimicrob Chemother (2011) 0.92
Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor. J Biol Chem (2014) 0.92
The two functional enoyl-acyl carrier protein reductases of Enterococcus faecalis do not mediate triclosan resistance. MBio (2013) 0.91
The impact of fatty acids on the antibacterial properties of N-thiolated β-lactams. Bioorg Med Chem Lett (2011) 0.90
Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis enoyl reductase (FabI) inhibitors. J Med Chem (2012) 0.90
Pseudomonas aeruginosa directly shunts β-oxidation degradation intermediates into de novo fatty acid biosynthesis. J Bacteriol (2012) 0.90
Fatty acids regulate stress resistance and virulence factor production for Listeria monocytogenes. J Bacteriol (2012) 0.89
The stearoyl-coenzyme A desaturase 1 is essential for virulence and membrane stress in Candida parapsilosis through unsaturated fatty acid production. Infect Immun (2010) 0.88
Structural basis for feed-forward transcriptional regulation of membrane lipid homeostasis in Staphylococcus aureus. PLoS Pathog (2013) 0.86
Triclosan promotes Staphylococcus aureus nasal colonization. MBio (2014) 0.84
Total syntheses of (+/-)-platencin and (-)-platencin. J Am Chem Soc (2009) 0.84
The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection. J Bacteriol (2012) 0.84
Extensive in vivo resilience of persistent Salmonella. PLoS One (2012) 0.83
Relaxed natural selection alone does not permit transposable element expansion within 4,000 generations in Escherichia coli. Genetica (2011) 0.82
Drug discovery: Not as fab as we thought. Nature (2009) 0.81
Identification of novel bacterial histidine biosynthesis inhibitors using docking, ensemble rescoring, and whole-cell assays. Bioorg Med Chem (2010) 0.81
The Biofilm Lifestyle Involves an Increase in Bacterial Membrane Saturated Fatty Acids. Front Microbiol (2016) 0.81
Inhibition of Candida parapsilosis fatty acid synthase (Fas2) induces mitochondrial cell death in serum. PLoS Pathog (2012) 0.80
The AirSR two-component system contributes to Staphylococcus aureus survival in human blood and transcriptionally regulates sspABC operon. Front Microbiol (2015) 0.80
Antibacterial sulfur-containing platensimycin and platencin congeners from Streptomyces platensis SB12029. Bioorg Med Chem (2016) 0.80
From microbial gene essentiality to novel antimicrobial drug targets. BMC Genomics (2014) 0.79
FabH mutations confer resistance to FabF-directed antibiotics in Staphylococcus aureus. Antimicrob Agents Chemother (2014) 0.78
Incorporation of exogenous fatty acids protects Enterococcus faecalis from membrane-damaging agents. Appl Environ Microbiol (2014) 0.78
Activation of Exogenous Fatty Acids to Acyl-Acyl Carrier Protein Cannot Bypass FabI Inhibition in Neisseria. J Biol Chem (2015) 0.78
Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI). Bioorg Med Chem Lett (2015) 0.78
Deletion of the β-acetoacetyl synthase FabY in Pseudomonas aeruginosa induces hypoacylation of lipopolysaccharide and increases antimicrobial susceptibility. Antimicrob Agents Chemother (2013) 0.78
Mechanisms of self-resistance in the platensimycin- and platencin-producing Streptomyces platensis MA7327 and MA7339 strains. Chem Biol (2014) 0.78
Bacterial fatty acid metabolism in modern antibiotic discovery. Biochim Biophys Acta (2016) 0.77
Dissemination of Novel Antimicrobial Resistance Mechanisms through the Insertion Sequence Mediated Spread of Metabolic Genes. Front Microbiol (2016) 0.77
Structural characterization and comparison of three acyl-carrier-protein synthases from pathogenic bacteria. Acta Crystallogr D Biol Crystallogr (2012) 0.77
PlsX deletion impacts fatty acid synthesis and acid adaptation in Streptococcus mutans. Microbiology (2016) 0.76
Platensimycin and platencin: Inspirations for chemistry, biology, enzymology, and medicine. Biochem Pharmacol (2016) 0.76
Environmental fatty acids enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted antimicrobials. Nat Commun (2016) 0.76
Mycobacterium tuberculosis metabolism. Cold Spring Harb Perspect Med (2014) 0.76
A Review on Platensimycin: A Selective FabF Inhibitor. Int J Med Chem (2016) 0.76
Transcriptional control of lipid metabolism by the MarR-like regulator FamR and the global regulator GlxR in the lipophilic axilla isolate Corynebacterium jeikeium K411. Microb Biotechnol (2012) 0.75
AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei--Crystal structure, mode of action, and biological activity. Protein Sci (2015) 0.75
Resistance Mechanisms and the Future of Bacterial Enoyl-Acyl Carrier Protein Reductase (FabI) Antibiotics. Cold Spring Harb Perspect Med (2016) 0.75
A Substrate Mimic Allows High-Throughput Assay of the FabA Protein and Consequently the Identification of a Novel Inhibitor of Pseudomonas aeruginosa FabA. J Mol Biol (2015) 0.75
Either fadD1 or fadD2, Which Encode acyl-CoA Synthetase, Is Essential for the Survival of Haemophilus parasuis SC096. Front Cell Infect Microbiol (2017) 0.75
Recent Advances in the Rational Design and Optimization of Antibacterial Agents. Medchemcomm (2016) 0.75
Antibiotics May Trigger Mitochondrial Dysfunction Inducing Psychiatric Disorders. Med Sci Monit (2017) 0.75
Selectivity of Pyridone- and Diphenyl Ether-Based Inhibitors for the Yersinia pestis FabV Enoyl-ACP Reductase. Biochemistry (2016) 0.75
FapR: From Control of Membrane Lipid Homeostasis to a Biotechnological Tool. Front Mol Biosci (2016) 0.75
Lactococcus lactis fabH, encoding beta-ketoacyl-acyl carrier protein synthase, can be functionally replaced by the Plasmodium falciparum congener. Appl Environ Microbiol (2010) 0.75
Clinical Relevance of Type II Fatty Acid Synthesis Bypass in Staphylococcus aureus. Antimicrob Agents Chemother (2017) 0.75
The natural diyne-furan fatty acid EV-086 is an inhibitor of fungal delta-9 fatty acid desaturation with efficacy in a model of skin dermatophytosis. Antimicrob Agents Chemother (2013) 0.75
Next-generation antimicrobials: from chemical biology to first-in-class drugs. Arch Pharm Res (2015) 0.75
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin. Bioorg Med Chem (2017) 0.75
Enoyl-Acyl Carrier Protein Reductase I (FabI) Is Essential for the Intracellular Growth of Listeria monocytogenes. Infect Immun (2016) 0.75
Growth-Environment Dependent Modulation of Staphylococcus aureus Branched-Chain to Straight-Chain Fatty Acid Ratio and Incorporation of Unsaturated Fatty Acids. PLoS One (2016) 0.75
Lipid A modification systems in gram-negative bacteria. Annu Rev Biochem (2007) 8.60
The mechanisms of action of PPARs. Annu Rev Med (2002) 6.71
Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature (2006) 5.81
Efficient insertional mutagenesis in lactococci and other gram-positive bacteria. J Bacteriol (1996) 4.96
Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease. Mol Microbiol (2002) 4.82
Membrane lipid homeostasis in bacteria. Nat Rev Microbiol (2008) 3.88
Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu Rev Microbiol (2001) 3.35
Assembly and role of pili in group B streptococci. Mol Microbiol (2006) 2.92
Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J Clin Invest (1971) 2.49
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc Natl Acad Sci U S A (2007) 2.43
Inhibition of beta-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism. J Biol Chem (2000) 2.39
In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345). Antimicrob Agents Chemother (1998) 2.13
Triclosan: applications and safety. Am J Infect Control (1996) 2.11
Inhibiting bacterial fatty acid synthesis. J Biol Chem (2006) 2.03
Escherichia coli FadR positively regulates transcription of the fabB fatty acid biosynthetic gene. J Bacteriol (2001) 1.68
Mechanistic diversity and regulation of Type II fatty acid synthesis. Biochem Soc Trans (2002) 1.46
Beta-ketoacyl-acyl carrier protein synthase III (FabH) is essential for bacterial fatty acid synthesis. J Biol Chem (2003) 1.45
The fabM gene product of Streptococcus mutans is responsible for the synthesis of monounsaturated fatty acids and is necessary for survival at low pH. J Bacteriol (2004) 1.40
Antibacterial targets in fatty acid biosynthesis. Curr Opin Microbiol (2007) 1.37
Respiration metabolism of Group B Streptococcus is activated by environmental haem and quinone and contributes to virulence. Mol Microbiol (2005) 1.24
Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med (2008) 1.20
Role of unsaturated fatty acid biosynthesis in virulence of Streptococcus mutans. Infect Immun (2007) 1.17
Serum fatty acid levels, dietary style and coronary heart disease in three neighbouring areas in Japan: the Kumihama study. Br J Nutr (2003) 1.15
Coexpression of virulence and fosfomycin susceptibility in Listeria: molecular basis of an antimicrobial in vitro-in vivo paradox. Nat Med (2006) 1.12
The Group B Streptococcus NADH oxidase Nox-2 is involved in fatty acid biosynthesis during aerobic growth and contributes to virulence. Mol Microbiol (2006) 1.07
Cerulenin-inhibited cells of Staphylococcus aureus resume growth when supplemented with either a saturated or an unsaturated fatty acid. Antimicrob Agents Chemother (1977) 1.06
Isolation and characterization of unsaturated fatty acid auxotrophs of Streptococcus pneumoniae and Streptococcus mutans. J Bacteriol (2007) 1.02
Cellular Fatty Acid profiles of lactobacillus and lactococcus strains in relation to the oleic Acid content of the cultivation medium. Appl Environ Microbiol (1995) 0.99
How fatty acids bind to proteins: the inside story from protein structures. Prostaglandins Leukot Essent Fatty Acids (2002) 0.96
Effects of polyunsaturated fatty acids in growth medium on lipid composition and on physicochemical surface properties of lactobacilli. Appl Environ Microbiol (2004) 0.96
Lipids in human parotid saliva with regard to caries experience. J Oleo Sci (2008) 0.92
PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab (2007) 7.19
Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev (2009) 5.11
Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease. Mol Microbiol (2002) 4.82
Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med (2004) 4.47
Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother (2005) 4.15
Accuracy of phenotypic and genotypic testing for identification of Streptococcus pneumoniae and description of Streptococcus pseudopneumoniae sp. nov. J Clin Microbiol (2004) 3.96
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest (2006) 3.48
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev (2006) 3.48
Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol (2004) 3.12
Assembly and role of pili in group B streptococci. Mol Microbiol (2006) 2.92
Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes (2006) 2.85
Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology (2013) 2.84
IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data. Nucleic Acids Res (2010) 2.75
Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology (2008) 2.73
Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab (2006) 2.70
Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways. Circ Res (2011) 2.60
Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res (2003) 2.58
Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest (2006) 2.55
Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology (2010) 2.53
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem (2006) 2.38
Overview of nomenclature of nuclear receptors. Pharmacol Rev (2006) 2.21
Sorting sortases: a nomenclature proposal for the various sortases of Gram-positive bacteria. Res Microbiol (2005) 2.20
Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res (2004) 2.16
Dual role for pilus in adherence to epithelial cells and biofilm formation in Streptococcus agalactiae. PLoS Pathog (2009) 2.15
Formation of D-alanyl-lipoteichoic acid is required for adhesion and virulence of Listeria monocytogenes. Mol Microbiol (2002) 2.15
Increased ABCA1 activity protects against atherosclerosis. J Clin Invest (2002) 2.13
Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler Thromb Vasc Biol (2008) 2.12
Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes (2004) 2.12
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A (2004) 2.08
Shaping a bacterial genome by large chromosomal replacements, the evolutionary history of Streptococcus agalactiae. Proc Natl Acad Sci U S A (2008) 2.06
Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha. Gastroenterology (2008) 2.06
Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol (2010) 2.03
Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol (2012) 2.02
Taxonomic dissection of the Streptococcus bovis group by analysis of manganese-dependent superoxide dismutase gene (sodA) sequences: reclassification of 'Streptococcus infantarius subsp. coli' as Streptococcus lutetiensis sp. nov. and of Streptococcus bovis biotype 11.2 as Streptococcus pasteurianus sp. nov. Int J Syst Evol Microbiol (2002) 2.01
Performance of chromID ESBL, a chromogenic medium for detection of Enterobacteriaceae producing extended-spectrum beta-lactamases. J Med Microbiol (2008) 2.01
TLR-independent type I interferon induction in response to an extracellular bacterial pathogen via intracellular recognition of its DNA. Cell Host Microbe (2008) 1.98
CovS/CovR of group B streptococcus: a two-component global regulatory system involved in virulence. Mol Microbiol (2004) 1.94
Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol Metab (2010) 1.93
Multiplex PCR assay for rapid and accurate capsular typing of group B streptococci. J Clin Microbiol (2007) 1.91
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol (2008) 1.88
Genomic diversity and evolution within the species Streptococcus agalactiae. Microbes Infect (2006) 1.86
Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab (2012) 1.86
The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem (2005) 1.85
The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol (2005) 1.84
The highly dynamic CRISPR1 system of Streptococcus agalactiae controls the diversity of its mobilome. Mol Microbiol (2012) 1.82
Current trends in rapid diagnostics for methicillin-resistant Staphylococcus aureus and glycopeptide-resistant enterococcus species. J Clin Microbiol (2008) 1.81
Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest (2002) 1.80
Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta (2007) 1.79
Peroxisome proliferator--activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation (2002) 1.79
Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci (2003) 1.78
Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor α in mouse liver reveals extensive sharing of binding sites. Mol Cell Biol (2011) 1.77
The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation. J Biol Chem (2003) 1.76
The SrtA Sortase of Streptococcus agalactiae is required for cell wall anchoring of proteins containing the LPXTG motif, for adhesion to epithelial cells, and for colonization of the mouse intestine. Infect Immun (2005) 1.75
Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes (2011) 1.73
Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties. Circ Res (2004) 1.72
ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver. J Clin Invest (2008) 1.71
Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription. J Lipid Res (2002) 1.71
Telomerase activation in atherosclerosis and induction of telomerase reverse transcriptase expression by inflammatory stimuli in macrophages. Arterioscler Thromb Vasc Biol (2010) 1.70
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol (2005) 1.68
Liver X receptor activation stimulates iron export in human alternative macrophages. Circ Res (2013) 1.66
Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. Gastroenterology (2003) 1.64
Genome sequence of Streptococcus gallolyticus: insights into its adaptation to the bovine rumen and its ability to cause endocarditis. J Bacteriol (2010) 1.64
Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Mol Endocrinol (2002) 1.63
Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes (2004) 1.63
Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha. Arterioscler Thromb Vasc Biol (2005) 1.63
Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol (2003) 1.61
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem (2006) 1.60
Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol (2003) 1.60
Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood (2002) 1.60
When the Clock stops ticking, metabolic syndrome explodes. Nat Med (2006) 1.59
PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest (2005) 1.58
Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J Clin Endocrinol Metab (2004) 1.58
Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes (2005) 1.58
Identification of the bacterial microflora in dairy products by temporal temperature gradient gel electrophoresis. Appl Environ Microbiol (2002) 1.57
A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci U S A (2005) 1.55
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res (2012) 1.55
Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J Biol Chem (2004) 1.55
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology (2003) 1.54
Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med (2003) 1.53
Attenuated virulence of Streptococcus agalactiae deficient in D-alanyl-lipoteichoic acid is due to an increased susceptibility to defensins and phagocytic cells. Mol Microbiol (2003) 1.53
Mitochondrial dysfunction as an arrhythmogenic substrate: a translational proof-of-concept study in patients with metabolic syndrome in whom post-operative atrial fibrillation develops. J Am Coll Cardiol (2013) 1.53
The surface protein HvgA mediates group B streptococcus hypervirulence and meningeal tropism in neonates. J Exp Med (2010) 1.51
SpxB regulates O-acetylation-dependent resistance of Lactococcus lactis peptidoglycan to hydrolysis. J Biol Chem (2007) 1.51
Bacillus cytotoxicus sp. nov. is a novel thermotolerant species of the Bacillus cereus Group occasionally associated with food poisoning. Int J Syst Evol Microbiol (2012) 1.51
Dietary trans-10,cis-12 conjugated linoleic acid induces hyperinsulinemia and fatty liver in the mouse. J Lipid Res (2002) 1.48
Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat Med (2013) 1.46
Dynamic hydroxymethylation of deoxyribonucleic acid marks differentiation-associated enhancers. Nucleic Acids Res (2012) 1.46
Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells. Arterioscler Thromb Vasc Biol (2007) 1.45
PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH. Atherosclerosis (2011) 1.44
Impact of endotoxin challenge in obese pigs. Shock (2014) 1.43